G

GRIMALDI LME

Last name: GRIMALDI LME

2017 (v1)

Publication

Metadata-only

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).

Comi G Patti F Rocca MA

No description

Uploaded on: April 14, 2023
2018 (v1)

Publication

Metadata-only

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

Prosperini L Annovazzi P Boffa L

In this retrospective, multicenter, real-world study we collected clinical and magnetic resonance imaging (MRI) data of all patients (n = 40) with relapsing-remitting multiple sclerosis (RRMS) treated with alemtuzumab according to a "free-of-charge" protocol available before the drug marketing approval in Italy. Almost all (39/40) started...

Uploaded on: April 14, 2023
2014 (v1)

Publication

Metadata-only

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.

Laroni A Brogi D Morra VB

In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate (HR) in the 6 hours after drug intake.The aim of the study is to to assess safety and tolerability of the first dose...

Uploaded on: April 14, 2023